Gilead $5.1 billion investment in Galapagos

Overview:

• US antiviral drugmaker Gilead will invest $5.1 billion in Belgo-Dutch biotech firm, Galapagos.
• Gilead will invest an initial $3.95 billion in order to expand and accelerate the biotech firm's research and development programme. In return Gilead will receive an exclusive product licence and option rights to develop and commercialise all Galapagos' current and future programmes in countries outside Europe.
• Gilead will also invest $1.1 billion in shares, increasing its stake in Galapagos from 12.3% to 22.1%.

Prin Shasiharan - Researcher